/AVDL
AVDL Stock - Avadel Pharmaceuticals plc
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$21.47+0.23%
+$0.05 (+0.23%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).38
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-5.9%upside
Target: $20.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AVDL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.26 – $21.68
TARGET (TP)$20.20
STOP LOSS$19.75
RISK/REWARD1:-0.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.26
52W High$23.57
52W Low$6.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $169.12M | $27.96M | N/A | N/A | $22.33M |
| Gross Profit | $153.84M | $27.12M | N/A | N/A | $16.59M |
| Gross Margin | 91.0% | 97.0% | N/A | N/A | 74.3% |
| Operating Income | $-42,399,000 | $-137,849,000 | $-98,561,000 | $-85,546,000 | $5.82M |
| Net Income | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 | $7.03M |
| Net Margin | -28.9% | -573.2% | N/A | N/A | 31.5% |
| EPS | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 |
Company Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
69%
Hold / Neutral
4
31%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
9 Bullish4 Neutral/Bearish
Price Targets
$17
Average Target
↓ 18.7% Downside
Now
$2
Low
$17
Average
$29
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 23rd 2025 | H.C. Wainwright | Downgrade | Neutral | $20 |
| September 3rd 2025 | Wells Fargo | Initiation | Equal Weight | $16 |
| July 18th 2025 | H.C. Wainwright | Resumed | Buy | $22 |
| February 11th 2025 | Deutsche Bank | Initiation | Buy | $12 |
| June 12th 2024 | Rodman & Renshaw | Initiation | Buy | $27 |
| March 5th 2024 | Oppenheimer | Reiterated | Outperform | $29← $27 |
| March 5th 2024 | H.C. Wainwright | Reiterated | Buy | $25← $21 |
| March 5th 2024 | Needham | Reiterated | Buy | $22← $20 |
| February 6th 2024 | UBS | Initiation | Buy | $21 |
| November 30th 2022 | Jefferies | Upgrade | Buy | $11← $6.5 |
| August 10th 2022 | Jefferies | Downgrade | Hold | $8← $6 |
| July 28th 2022 | Craig Hallum | Resumed | Buy | $12← $15.5 |
| May 26th 2022 | Stifel | Downgrade | Hold | $2← $9 |
Earnings History & Surprises
AVDLBeat Rate
29%
Last 17 quarters
Avg Surprise
+12.8%
EPS vs Estimate
Beats / Misses
5/10
2 met exactly
Latest EPS
$0.10
Q3 2025
EPS Surprise History
Q4 23
-17.1%
$-0.41vs$-0.35
Q1 24
-14.3%
$-0.32vs$-0.28
Q2 24
-20.0%
$-0.30vs$-0.25
Q3 24
+17.6%
$-0.14vs$-0.17
Q4 24
+50.0%
$-0.03vs$-0.06
Q1 25
0.0%
$-0.05vs$-0.05
Q2 25
+28.6%
$-0.05vs$-0.07
Q3 25
+400.0%
$0.10vs$0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.04 | — | — | — |
Q3 2025 | Aug 7, 2025 | $0.02 | $0.10 | +400.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q1 2024 | Mar 4, 2024 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.39 | $-0.70 | -79.5% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.37 | $-0.48 | -29.7% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.30 | $-0.44 | -46.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.22 | $-0.33 | -50.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.41 | $-0.50 | -22.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.44 | $-0.45 | -2.3% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.42 | $-0.38 | +9.5% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.38 | $-0.38 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Latest News
Avadel Pharmaceuticals Completes Enrollment In Phase 3 REVITALYZ Trial Of Once-At-Bedtime LUMRYZ For Idiopathic Hypersomnia, Data Expected In Q2 2026
📈 PositiveBenzinga•Dec 18, 2025, 12:02 PM
Alkermes To Acquire Avadel Pharmaceuticals In Shareholder Scheme, Sends Proposal To Equity And Employee Share Purchase Plan Holders
📉 NegativeBenzinga•Dec 5, 2025, 09:03 PM•Also:
Wells Fargo Maintains Equal-Weight on Avadel Pharmaceuticals, Raises Price Target to $22.5
📈 PositiveBenzinga•Nov 20, 2025, 03:42 PM
AVDL stock has given up its prior gain. Avadel Pharmaceuticals shares were trading higher after Alkermes increased the buyout offer to up to $22.50 per share.
➖ NeutralBenzinga•Nov 19, 2025, 11:42 AM•Also:
Avadel Pharmaceuticals shares are trading higher after Alkermes increased the buyout offer to up to $22.50 per share.
📈 PositiveBenzinga•Nov 19, 2025, 11:06 AM•Also:
Alkermes Has Increased The Buyout For Avadel Pharmaceuticals To Up To $22.50 Per Share, Consisting Of $21.00 In Cash And 1 Contingent Value Right Of Additional Cash Payment Of $1.50 Per Share
📈 PositiveBenzinga•Nov 19, 2025, 11:02 AM•Also:
Avadel Pharmaceuticals' Board Of Directors Has Determined That The Unsolicited Proposal From H. Lundbeck Constitutes A "Company Superior Proposal" Over The Existing Transaction Agreement With Alkermes
📈 PositiveBenzinga•Nov 17, 2025, 10:47 AM•Also: ,
Alkermes Says It Is Considering Options After Avadel Discloses Possible Lundbeck Offer And Highlights Avadel's Ongoing Obligation To Negotiate Under Existing Transaction Agreement
➖ NeutralBenzinga•Nov 14, 2025, 12:47 PM•Also:
Avadel climbs as Lundbeck outbids Alkermes in latest bidding war
📈 PositiveSeeking Alpha•Nov 14, 2025, 11:57 AM•Also:
Avadel Board Says Lundbeck Proposal May Be A Company Superior Proposal While Keeping Support For Existing Alkermes Deal Offering Up To $20 Per Share
➖ NeutralBenzinga•Nov 14, 2025, 10:51 AM•Also:
Avadel Receives Unsolicited Lundbeck Proposal Valuing Company At Up To $23 Per Share With $21 Cash Plus Up To $2 In CVR Milestones
📈 PositiveBenzinga•Nov 14, 2025, 10:51 AM
Wells Fargo Maintains Equal-Weight on Avadel Pharmaceuticals, Raises Price Target to $20
📈 PositiveBenzinga•Nov 7, 2025, 06:48 PM
Avadel Pharmaceuticals Q3 EPS $0.00 Misses $0.07 Estimate, Sales $77.467M Beat $73.574M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 09:37 PM
UBS Downgrades Avadel Pharmaceuticals to Neutral, Maintains Price Target to $20
➖ NeutralBenzinga•Oct 28, 2025, 11:51 AM
Leerink Partners Downgrades Avadel Pharmaceuticals to Market Perform, Announces $18.5 Price Target
📉 NegativeBenzinga•Oct 23, 2025, 09:52 PM•Also:
HC Wainwright & Co. Downgrades Avadel Pharmaceuticals to Neutral, Lowers Price Target to $20
➖ NeutralBenzinga•Oct 23, 2025, 11:59 AM
Jefferies Downgrades Avadel Pharmaceuticals to Hold, Lowers Price Target to $20
📉 NegativeBenzinga•Oct 22, 2025, 04:07 PM•Also:
Needham Downgrades Avadel Pharmaceuticals to Hold
📉 NegativeBenzinga•Oct 22, 2025, 02:37 PM
Avadel settles with Jazz Pharma; agrees to be acquired by Alkermes
📈 PositiveSeeking Alpha•Oct 22, 2025, 11:20 AM•Also: ,
Trading Halt: Halt status updated at 7:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 22, 2025, 11:15 AM
Frequently Asked Questions about AVDL
What is AVDL's current stock price?
Avadel Pharmaceuticals plc (AVDL) is currently trading at $21.47 per share. The stock has moved +0.23% today.
What is the analyst price target for AVDL?
The average analyst price target for AVDL is $20.20, based on 1 analyst.
What sector is Avadel Pharmaceuticals plc in?
Avadel Pharmaceuticals plc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is AVDL's market cap?
Avadel Pharmaceuticals plc has a market capitalization of $2.08 billion, making it a mid-cap company.
Does AVDL pay dividends?
No, Avadel Pharmaceuticals plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
ANIP
ANI Pharmaceuticals, Inc.
$82.85
Mkt Cap: $1.9B
BGM
BGM Group Ltd.
$4.36
Mkt Cap: $0.9B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
GRDN
Guardian Pharmacy Services, Inc.
$31.54
Mkt Cap: $2.0B
MD
Pediatrix Medical Group, Inc.
$21.91
Mkt Cap: $1.9B
OGN
Organon & Co.
$6.83
Mkt Cap: $1.8B
PAHC
Phibro Animal Health Corporation
$37.25
Mkt Cap: $1.5B
QDEL
QuidelOrtho Corporation
$28.95
Mkt Cap: $2.0B
TLRY
Tilray Brands, Inc.
$11.16
Mkt Cap: $1.2B
Explore stocks similar to AVDL for comparison